Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating
Source: SeekingAlpha
2026-03-10 14:08:54 ET
The last time I spoke about Dianthus Therapeutics, Inc. ( DNTH ), it was in a Seeking Alpha article entitled " Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition ." With respect to this article, I mentioned that the company was in the process of developing claseprubart [known as DNTH103 at that time] for the treatment of patients with Myasthenia Gravis [MG] in the ongoing phase 2 MaGic trial. I had a Buy rating at that time, and the stock has gained 174.53% since then....
Read the full article on Seeking Alpha
For further details see:
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating
Dianthus Therapeutics Inc.
NASDAQ: DNTH
DNTH Trading
0.62% G/L:
$82.32 Last:
744,399 Volume:
$81.08 Open:
DNTH Latest News
March 10, 2026 10:54:01 pm
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
March 09, 2026 04:01:00 pm
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
DNTH Stock Data
$2,196,597,434
37,892,819
0.47%
33
N/A
Biotechnology & Life Sciences
Healthcare
US
New York
